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Summary Reduced glutathione (GSH) has been demonstrated in benign and malignant human breast lesions
using a newly.developed histofluorescence technique. GSH was present in every lesion and in each case was
localised to the epithelium. A semi-quantitative assessment revealed a moderate amount of GSH in normal
epithelium and fibroadenoma and a high level in apocrine metaplasia, epitheliosis and intraduct carcinoma.
Invasive ductal carcinoma contained a variable amount of GSH. Correlation between fluorescence intensity
and histological grade of ductal carcinomas was almost statistically significant but a relationship to oestrogen
receptor status was not detected. The rapid assessment of GSH in breast cancer may aid in the selection of
optimum chemotherapeutic regimens.
Reduced glutathione (GSH) is a thiol containing tripeptide
which is involved in a variety of cellular functions. GSH has
a role in the detoxification of drugs and carcinogens,
protection of cells from free radical damage and reactive
oxygen compounds, participates in protein and DNA
synthesis and in the regulation of enzyme activity (Meister &
Anderson, 1983; Orrenius & Moldeus, 1984; Chasseaud,
1979). Altered levels of GSH are frequently observed in
experimental animal neoplasia (Roomi et al., 1985, Fiala et
al., 1976) but GSH levels in human neoplasia have been
reported only for carcinomas of the stomach and colon
(Siegers et al., 1983; Siegers et al., 1984). GSH in human
breast tissue has not been investigated previously, although
GSH-associated enzymes have been studied both
biochemically (Di Ilio et al., 1985) and histochemically
(Levine et al., 1983; Bard et al., 1986).
Tumour GSH appears to be an important factor in
determining the effectiveness of a variety of anti-cancer
chemotherapeutic drugs, in general a low level of GSH being
associated with increased chemotherapeutic efficiency (Arrick
& Nathan, 1984; Romine and Kessel, 1986; Crook et al.,
1986).
We have studied the localisation and amount of GSH in
normal and pathological human breast tissue using our
recently developed specific histofluorescence method for
GSH (Murray et al., 1986).
Materials and methods
Breast tissue
Breast tissue for this study was obtained from biopsies
submitted for frozen section diagnosis to the Department of
Pathology, University of Aberdeen. Usually one
representative block (up to 1.5 x 1.5 x 1 cm) was taken from
each biopsy. Four consecutive 30gm sections were used for
the demonstration of GSH. Two 8gm sections were stained
with toluidine blue and haematoxylin and eosin respectively
for diagnostic purposes.
Cytochemical demonstration ofGSH
Sections were fixed in 20% phosphate-buffered formalin
(pH8) for 10min and then reacted with o-phthalaldehyde
(Sigma Chemical Co Ltd, Poole, Dorset, prepared as a
10mM solution in methanol and used at a 1 in 10 dilution in
0.1 M phosphate:5 mm EDTA buffer, pH 8) for 60 min.
Under those conditions of fixation and pH o-phthalaldehyde
reacts specifically with GSH to form a blue fluorophor
which can be detected by fluorescence microscopy (Murray
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et al., 1986). Fixation with formalin blocks the reactivity
with o-phthalaldehyde of other potentially reactive sub-
stances such as the polyamines. One section was left
unreacted as a control. The sections were thoroughly washed
in distilled water, mounted in phosphate buffered glycerol
and then examined with a Leitz Orthoplan fluorescence
microscope fitted with a Ploem illuminator (dichroic mirror)
for epi-illumination (set at position 1, 50% transmission at
400 nm), a UGI excitation filter (band pass filter, peak
transmission 365nm) and a K430 high pass emission filter
(50% transmission at 430 nm).
The distribution of fluorescence in each section was
recorded and the intensity of GSH fluorescence assessed in
semi-quantitatively on a 4-point scale (0=no fluorescence,
+ =slight fluorescence, + + =moderate fluorescence,
+ + + =bright fluorescence).
Relationship between GSH concentration and
histofluorescence
Five known concentrations of authentic GSH (2, 4, 6, 8,
10mM) in 0.1 M formic acid were each mixed with 1%
polyvinylpyrrolidone (PVP: 2 ml GSH solution plus 1 ml
PVP), droplets applied to glass slides and then dried in air.
The slides were then reacted with o-phthalaldehyde as
described above, examined with fluorescence microscopy and
the fluorescence intensity assessed semi-quantitatively.
Grading ofinvasive ductal carcinomas
Invasive ductal carcinomas were graded according to the
criteria of Bloom and Richardson (1957) as modified by
Elston (1984).
Oestrogen receptor status
Oestrogen receptors in breast carcinomas were assayed using
a radiometric assay based on the method of Korenman
(1968). The tumours were considered positive when the
receptor level was greater than 10 fmolmg1 protein.
Statistics
Qualitative correlations between GSH content, histological
grade and oestrogen receptor status were assessed using the
Chi Squared (X2) test.
Results
The intensity of histofluorescence of authentic GSH in PVP
increased with increasing GSH concentration. GSH
concentrations of 2 and 4mM showed slight fluorescence
(+), 6 and 8 mM GSH showed moderate fluorescence (+ +)
and 10mM GSH showed bright fluorescence (+ + +).
Br. J. Cancer (1987), 55, 605-609 (--I The Macmillan Press Ltd., 1987606 G.I. MURRAY et al.
Table I Histopathological diagnosis and relative fluorescence of common breast lesions
Fluorescence
Diagnosis Patient age
(number ofbiopsies studied) mean (range) Site Relative intensity
Normal (5) 38 Epithelium of ducts
(33-47) and acini + +
Connective tissue 0
Fat 0
Simple cystic 39 Epithelium of
disease (30) (26-55) flattened cysts +
Normal epithelium + +
Apocrine metaplasia + + +
Epitheliosis (9) 45 Hyperplastic
(37-69) epithelium + + +
Fibroadenoma (23) 31 Epithelium + +
(18-50) Stroma 0
In-situ 48
carcinoma (3) (41-59) Epithelium + + +
Invasive ductal 58
carcinoma (39) (36-82) Epithelium + to +++
Table II Histopathological diagnosis and relative fluorescence of uncommon breast
lesions
Fluorescence
Diagnosis Patient age
(number ofbiopsies studied) mean (range) Site Relative intensity
Gynaecomastia (3) 55 Epithelium + +
(22-78)
Infiltrating lobular
carcinoma (1) 64 Epithelium + +
Phyllodes tumour (1) 56 Epithelium + +
Stroma +
Intraduct papilloma (1) 54 Papillary
epithelium + +
Papillary carcinoma (1) 73 Epithelium + +
A total of 116 breast biopsies were studied, including 5
normal biopsies, 30 biopsies with the features of simple
cystic disease, 9 examples of moderate epitheliosis (ductal
epithelial hyperplasia) without atypia, 23 fibroadenoma and
39 invasive ductal carcinomas (Tables I and II) in which
tumour heterogeneity was not apparent.
GSH was demonstrated in every breast biopsy studied and
in each case GSH was localised to the epithelium. Sites of
GSH were identified by light blue fluorescence of variable
intensity. This was readily differentiated from the much less
intense, bluish-white autofluorescence of collagen and elastic
fibres. Areas of fatty tissue showed no fluorescence.
Normal acinar and ductal epithelium consistently showed
a moderate amount of GSH-type fluorescence in either
normal (Figure 1) or abnormal biopsies. The flattened
epithelium lining simple breast cysts showed only slight
GSH-type fluorescence, whereas the apocrine epithelium
lining apocrine cysts was brightly fluorescent (Figure 2).
Similarly, the hyperplastic epithelium of hyperplastic cystic
disease also showed bright GSH-type fluorescence (Figure 3).
The neoplastic epithelium of fibroadenoma gave a
moderate amount of GSH-type fluorescence, whereas the
surrounding stroma showed only slight autofluorescence
(Figure 4). The single phyllodes tumour in the study also
showed a moderate amount of epithelial GSH-type
fluorescence, whereas the cellular stroma in this case gave
slight GSH-type fluorescence (Table II).
GSH was demonstrated in all invasive ductal carcinomas
studied, being localised in each case to the malignant
epithelium (Figure 5). The intensity of the GSH-type fluor-
escence was variable between tumours, with 14 tumours
showing slight fluorescence, 15 tumours showing moderate
fluorescence and 10 tumours with bright fluorescence,
whereas, intratumour variation was not noted. Eight of the
invasive ductal carcinomas contained areas of intraduct
carcinoma. These areas always demonstrated bright GSH-
type fluorescence, irrespective of the intensity of the
fluorescence of the invasive component. The three biopsies
which contained only intraduct carcinoma also showed
bright GSH-type fluorescence.
The intensity of GSH-type fluorescence in the invasive
ductal carcinomas was compared with two parameters that
are prognostically significant and for which data was
available on all the invasive ductal carcinomas in the study.
The tumours were graded histologically and 6 grade 1, 17
grade 2 and 16 grade 3 tumours were included in the study.
The correlation between the histological grade of the tumour
and its GSH content did not quite reach significance at the
0.05 level (X2 =6.95, 0.1 >P>0.05) (Table III). The study
contained 25 oestrogen receptor positive tumours and 14
Table III Relationship between GSH
level and histological grade of invasive
ductal carcinomaa
GSH level
Grade + + + + + +
1 1 4 1
2 6 8 3
3 7 3 6
aNumbers in the table indicate the
number of tumours in each grade and
GSH level category. X2 =6.95 (4 degrees
of freedom, 0.1 >P>0.05).9
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Figure 1 (A) A normal breast lobule showing localisation of
GSH (30,pm section) only to the acinar and ductal epithelium,
with no GSH present in the surrounding connective tissue or fat.
(B) Identical area from a parallel section stained with
haematoxylin and eosin. ( x 420. Scale bar represents 50 pm.)
Figure 3 (A) Hyperplastic ductal epithelium with a large
amount of GSH. (B) Identical area from a parallel haematoxylin
and eosin stained section. ( x 420. Scale bar represents 50pm.)
Figure 2 (A) A group of cysts lined by apocrine epithelium
containing a large amount of GSH. (B) Identical area from a
parallel section stained with haematoxylin and eosin. ( x 420.
Scale bar represents 50pm.)
Figure 4 (A) A fibroadenoma showing a moderate amount of
GSH present in the epithelium and none in the stroma or fat.
(B) Identical area from a parallel section stained with
haematoxylin and eosin. ( x 160. Scale bar represents 120 pm.)608 G.I. MURRAY et al.
Figure 5 (A) A grade 3 oestrogen receptor-positive invasive
ductal carcinoma containing a moderate amount of GSH.
(B) Identical area from a parallel section stained with
haematoxylin and eosin. ( x 420. Scale bar represents 50 rim.)
Table IV Relationship between GSH
level and oestrogen receptor status
(ORS) of invasive ductal carcinomaa
GSH level
+ ++ +++
ORS
Negative 4 7 3
Positive 10 8 7
aNumbers in the table indicate the
number of tumours in each GSH level
category and their oestrogen receptor
status. X2=1.23 (2 degrees of freedom,
P>0.1).
oestrogen receptor negative tumours. There was, however, no
significant relationship between oestrogen receptor status and
GSH content (X2 = 1.23, P>0.1) (Table IV).
Discussion
We have localised and estimated GSH in normal breast
tissue and a variety of pathological breast biopsies using a
newly developed specific histofluorescence method, which
requires the use of thick sections to prevent the loss of GSH
(Murray et al., 1986). The intensity of the observed fluor-
escence was assessed semi-quantitatively and used as an
indicator of intracellular GSH content.
The localisation of GSH to the epithelium in every breast
biopsy except one, a phyllodes tumour, where GSH was
present also in the stroma, is consistent with the observation
that GSH is predominantly present in epithelial tissues
(Meister & Anderson, 1983).
Normal acinar and ductal epithelium present either in
normal or abnormal biopsies always contained a moderate
amount of GSH. Simple cysts lined by flattened epithelium
contained a small amount of GSH, whereas apocrine
epithelium consistently contained a large amount of GSH.
Apocrine epithelium has a number of characteristic bio-
chemical properties, of which one is a high level of glucose-6-
phosphate dehydrogenase (Petersen et al., 1985), an enzyme
involved in the production of reduced nicotinamide adenine
dinucleotide phosphate (NADPH). The generation of
NADPH will strongly favour the production of GSH from
oxidised glutathione by glutathione reductase (Meister &
Anderson, 1983; Kaplowitz et al., 1985).
Consistently high levels of GSH were also observed in
epitheliosis and intraduct carcinoma. This observation is
similar to that reported for experimental neoplasia, where
pre-neoplastic foci have an increased GSH level (measured
biochemically) (Roomi et al., 1985) and show increased
staining with mercury orange presumably due to increased
GSH (Demle & Oesterle, 1980).
By implication from the evidence discussed above, the high
GSH content of apocrine epithelium might suggest that this
represents a pre-neoplastic change. This is consistent with
epidemiological evidence that the presence of apocrine
metaplasia carries an increased risk of developing breast
cancer (Dixon et al., 1985).
We have demonstrated GSH to be present in all invasive
ductal carcinomas and also that there was intertumour
variation in GSH content. There were approximately equal
numbers of tumours with low, moderate and high GSH
content. The variable level of GSH in breast carcinomas
presumably reflects alterations in GSH metabolism as y-
glutamyl transpeptidase activity shows similar variation
(Bard et al., 1986). GSH content was compared with histo-
logical grade and oestrogen receptor status, prognostically
important variables for which information was available for
all the tumours (Paterson et al., 1982; Elston, 1984). There
was a correlation between GSH and histological grade
although this did not reach statistical significance at the 0.05
level but not between GSH content and oestrogen receptor
status. Previous biochemical measurements of GSH in
carcinomas of the stomach and colon have demonstrated a
trend to a reduction in GSH although possible inter tumour
variation was not commented upon (Siegers et al., 1983;
1984).
Recently it has been proposed that tumour GSH is an
important factor influencing the effectiveness of a variety of
cancer chemotherapeutic agents (Arrick & Nathan, 1984;
Russo & Mitchell, 1985; Hamilton et al., 1985): these authors
state that tumours with a low GSH content will be more
susceptible to the action of these agents, whereas tumours
with a high GSH level will be protected and therefore
resistant. However, in normal tissues a high GSH content is
desirable to protect them from the toxicity of these anti-
cancer agents.
GSH levels (measured biochemically) in normal and
tumour cells can be altered pharmacologically in vitro
(Meister, 1984; Griffith & Meister, 1979; Brodie & Reed,
1985). It has been demonstrated recently that GSH levels in
normal and tumour cells can be differentially manipulated to
produce a low level of GSH in tumour cells and a high level
of GSH in normal cells (Russo et al, 1986), thereby
rendering the tumour cells more susceptible to the action of
certain anti-cancer agents and protecting the normal cells.
The development of improved regimens for anti-cancer
agents, based on a knowledge of cellular GSH levels, could
be greatly aided by this new histofluorescence procedure for
assessing GSH level in tissue biopsies.
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